1. Home
  2. ARQT vs NIC Comparison

ARQT vs NIC Comparison

Compare ARQT & NIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARQT
  • NIC
  • Stock Information
  • Founded
  • ARQT 2016
  • NIC 2000
  • Country
  • ARQT United States
  • NIC United States
  • Employees
  • ARQT N/A
  • NIC N/A
  • Industry
  • ARQT Biotechnology: Pharmaceutical Preparations
  • NIC Major Banks
  • Sector
  • ARQT Health Care
  • NIC Finance
  • Exchange
  • ARQT Nasdaq
  • NIC Nasdaq
  • Market Cap
  • ARQT 1.7B
  • NIC 1.8B
  • IPO Year
  • ARQT 2020
  • NIC N/A
  • Fundamental
  • Price
  • ARQT $13.82
  • NIC $116.70
  • Analyst Decision
  • ARQT Strong Buy
  • NIC Buy
  • Analyst Count
  • ARQT 6
  • NIC 4
  • Target Price
  • ARQT $18.80
  • NIC $119.25
  • AVG Volume (30 Days)
  • ARQT 2.0M
  • NIC 72.3K
  • Earning Date
  • ARQT 08-13-2025
  • NIC 07-15-2025
  • Dividend Yield
  • ARQT N/A
  • NIC 1.10%
  • EPS Growth
  • ARQT N/A
  • NIC 28.66
  • EPS
  • ARQT N/A
  • NIC 8.31
  • Revenue
  • ARQT $212,819,000.00
  • NIC $352,932,000.00
  • Revenue This Year
  • ARQT $61.15
  • NIC N/A
  • Revenue Next Year
  • ARQT $37.98
  • NIC $4.08
  • P/E Ratio
  • ARQT N/A
  • NIC $14.05
  • Revenue Growth
  • ARQT 100.03
  • NIC 9.54
  • 52 Week Low
  • ARQT $7.86
  • NIC $77.49
  • 52 Week High
  • ARQT $17.75
  • NIC $125.50
  • Technical
  • Relative Strength Index (RSI)
  • ARQT 50.73
  • NIC 42.54
  • Support Level
  • ARQT $12.97
  • NIC $115.57
  • Resistance Level
  • ARQT $13.84
  • NIC $118.58
  • Average True Range (ATR)
  • ARQT 0.61
  • NIC 2.11
  • MACD
  • ARQT 0.02
  • NIC -0.55
  • Stochastic Oscillator
  • ARQT 51.64
  • NIC 16.97

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About NIC Nicolet Bankshares Inc.

Nicolet Bankshares Inc is a United States-based bank holding company's principal business is banking, consisting of lending and deposit gathering, as well as ancillary banking-related products and services, to businesses and individuals of the communities it serves, and the operational support to deliver, fund and manage. It offers a variety of loans, deposits, and related services to business customers especially small and medium-sized businesses and professional concerns, business deposit products, cash management services, international banking services, business loans, lines of credit, commercial real estate financing, construction loans, agricultural real estate or production loans, and letters of credit, as well as retirement plan services.

Share on Social Networks: